A compound liver-protecting traditional Chinese medicine for treating non-alcoholic fatty liver

A non-alcoholic and fatty liver technology, applied in the field of compound liver-protecting traditional Chinese medicine for the treatment of non-alcoholic fatty liver, can solve the problems of reducing absorption, increasing carotenoid absorption, etc. Effects of side effects

Inactive Publication Date: 2018-02-09
QINGDAO MUNICIPAL HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A high-cholesterol diet may increase carotenoid absorption whereas a low-fat diet decreases its absorption

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A compound liver-protecting traditional Chinese medicine for treating non-alcoholic fatty liver
  • A compound liver-protecting traditional Chinese medicine for treating non-alcoholic fatty liver
  • A compound liver-protecting traditional Chinese medicine for treating non-alcoholic fatty liver

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1, In Vitro Experiment of the Compound Liver-Protecting Traditional Chinese Medicine in Treating Nonalcoholic Fatty Liver

[0040] 1. Liquid preparation

[0041] (1) Preparation of 1% (w / w) PBS buffer

[0042] Weigh 2.0g of PBS powder into a 250mL jar, add 200mL of double-distilled water to dissolve, sterilize by high-pressure steam, and store in an ordinary refrigerator at 4°C.

[0043] (2) Preparation of cell culture medium (10% of fetal bovine serum and 1% of penicillin and streptomycin)

[0044] In the ultra-clean bench, add 15 mL of fetal bovine serum to a jar (250 mL), then add 1.5 mL of double antibody (penicillin and streptomycin), and finally add an appropriate amount of RPMI-1640 culture solution to make the volume to 150 mL, filter and sterilize, Store in a normal refrigerator at 4°C.

[0045] (3) Preparation of cell cryopreservation solution

[0046] Add 7mL of RPMI-1640 culture medium, 2mL of fetal bovine serum and 1mL of DMSO into a centrifuge ...

Embodiment 2

[0098] Example 2, In Vivo Experiment of the Compound Liver-Protecting Traditional Chinese Medicine in Treating Non-alcoholic Fatty Liver

[0099] 1. Experimental materials

[0100] 1.1 Experimental animals

[0101] C57BL / 6J male mice were purchased from Beijing Weitong Lihua Company, SPF grade, weighing 18-22 g. The compound liver-protecting traditional Chinese medicine was purchased from Dalian Zhongke Geleike Biotechnology Co., Ltd. The experimental animals were kept under SPF standard laboratory conditions, kept well ventilated, the ambient temperature was controlled at 23°C±2°C, the humidity was controlled at 40%-50%, 12h light / 12h dark cycle, and free intake of food and water. The mice were fed normally for 1 week before the start of the study, and the experiment started from the 2nd week.

[0102] 1.2 Feed formula

[0103] 10% of the energy in the basic feed comes from fat, 70% from carbohydrates, and 20% from protein. 45% of the energy in a high-fat diet comes from f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to view more

Abstract

The invention provides a compound liver-protecting traditional Chinese medicine for treating non-alcoholic fatty liver, which comprises the following components in parts by weight: 2-10 parts by weight of chitosan oligosaccharide, 3-20 parts by weight of salidroside, 5-10 parts by weight of resveratrol, 10-20 parts by weight of astaxanthin and 5-15 parts by weight of sea cucumber glycosaminoglycan. In the present invention, through in vivo and in vitro experiments on NAFLD mouse models, five bioactive components of salidroside, chitosan, resveratrol, chitosan and sea cucumber glycosaminoglycans have been determined by cell and molecular biology methods. After the scientific proportioning, it can regulate the genes related to lipid metabolism, significantly reduce the content of triglyceride in NAFLD liver cells, reduce the apoptosis induced by fatty acids, reduce the hepatic steatosis of high-fat diet mice, and reduce the intrahepatic TG content, and no obvious side effects, no cytotoxicity, will not destroy the body's own immune balance.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a compound liver-protecting traditional Chinese medicine for treating non-alcoholic fatty liver. technical background [0002] Nonalcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by steatosis, necrosis, inflammatory cell infiltration, and fat accumulation in hepatic parenchymal cells. Fatty liver (NAFL), steatohepatitis (NASH) and related cirrhosis. Nonalcoholic fatty liver disease has become the leading cause of chronic liver disease in western developed countries. In my country, NAFLD is the second most common liver disease after chronic viral hepatitis. The pathogenesis of NAFLD is very complex, mostly caused by factors such as obesity, diabetes, hyperlipidemia, insulin resistance and metabolic disorder syndrome affecting liver fat metabolism. NAFLD can coexist with other chronic liver diseases, and can exacerbate liver dam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/737A61P1/16A61K31/7032A61K31/702A61K31/722A61K31/122A61K31/05
Inventor 张健隋牮箐栾桂萍金文文
Owner QINGDAO MUNICIPAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap